Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer

Howard Gurney; Edson Sydney de Campos; David Dodwell; Arvind Kamthan; Nicholas Thatcher

doi:10.1016/0277-5379(91)90218-3

Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer

Howard Gurney, Edson Sydney de Campos^*, David Dodwell, Arvind Kamthan, Nicholas Thatcher

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m², mesna 1.5 g/m² and mitomycin 1.2 mg/m² daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10 42 patients (23.8%) and stable disease in 25 42 (59.5%). The Karnofsky performance status (KP) improved in 10 42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity.

Original language	English
Pages (from-to)	565-567
Number of pages	3
Journal	European Journal of Cancer and Clinical Oncology
Volume	27
Issue number	5
DOIs	https://doi.org/10.1016/0277-5379(91)90218-3
Publication status	Published - 1991
Externally published	Yes

Access to Document

10.1016/0277-5379(91)90218-3

Cite this

@article{df946c0353ce44f39e34460fc5d8ec2e,

title = "Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer",

abstract = "42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10 42 patients (23.8%) and stable disease in 25 42 (59.5%). The Karnofsky performance status (KP) improved in 10 42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity.",

author = "Howard Gurney and {de Campos}, {Edson Sydney} and David Dodwell and Arvind Kamthan and Nicholas Thatcher",

year = "1991",

doi = "10.1016/0277-5379(91)90218-3",

language = "English",

volume = "27",

pages = "565--567",

journal = "European Journal of Cancer and Clinical Oncology",

issn = "0277-5379",

publisher = "Pergamon Press",

number = "5",

}

TY - JOUR

T1 - Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer

AU - Gurney, Howard

AU - de Campos, Edson Sydney

AU - Dodwell, David

AU - Kamthan, Arvind

AU - Thatcher, Nicholas

PY - 1991

Y1 - 1991

N2 - 42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10 42 patients (23.8%) and stable disease in 25 42 (59.5%). The Karnofsky performance status (KP) improved in 10 42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity.

AB - 42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10 42 patients (23.8%) and stable disease in 25 42 (59.5%). The Karnofsky performance status (KP) improved in 10 42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity.

UR - http://www.scopus.com/inward/record.url?scp=0025782959&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(91)90218-3

DO - 10.1016/0277-5379(91)90218-3

M3 - Article

C2 - 1647182

AN - SCOPUS:0025782959

SN - 0277-5379

VL - 27

SP - 565

EP - 567

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

IS - 5

ER -

Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer

Abstract

Access to Document

Other files and links

Fingerprint

Cite this